Drug Profile
OXS 1650
Alternative Names: dCD133KDELLatest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator University of Minnesota
- Developer Oxis Biotech; University of Minnesota
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Intraperitoneal, Injection)
- 31 Mar 2017 Oxis Biotech has patents pending covering therapeutic compounds and its uses in USA
- 27 Mar 2013 Preclinical trials in Ovarian cancer in USA (Intraperitoneal)